| 000 | 01511 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250516030359.0 | ||
| 264 | 0 | _c20120409 | |
| 008 | 201204s 0 0 eng d | ||
| 022 | _a1095-953X | ||
| 024 | 7 |
_a10.1016/j.nbd.2011.03.005 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHorvath, Tamas L | |
| 245 | 0 | 0 |
_aGPA protects the nigrostriatal dopamine system by enhancing mitochondrial function. _h[electronic resource] |
| 260 |
_bNeurobiology of disease _cJul 2011 |
||
| 300 |
_a152-62 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCorpus Striatum _xdrug effects |
| 650 | 0 | 4 |
_aDopamine _xmetabolism |
| 650 | 0 | 4 |
_aGuanidines _xpharmacology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred C57BL |
| 650 | 0 | 4 |
_aMitochondria _xdrug effects |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aParkinsonian Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aPropionates _xpharmacology |
| 650 | 0 | 4 |
_aSubstantia Nigra _xdrug effects |
| 650 | 0 | 4 |
_aUp-Regulation _xdrug effects |
| 700 | 1 | _aErion, Derek M | |
| 700 | 1 | _aElsworth, John D | |
| 700 | 1 | _aRoth, Robert H | |
| 700 | 1 | _aShulman, Gerald I | |
| 700 | 1 | _aAndrews, Zane B | |
| 773 | 0 |
_tNeurobiology of disease _gvol. 43 _gno. 1 _gp. 152-62 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.nbd.2011.03.005 _zAvailable from publisher's website |
| 999 |
_c20677394 _d20677394 |
||